Кардиоренальный и нейрогормональный континуум у больных артериальной гипертензией, его значение в клинической практике
About the Authors
Ш. АхадовRussian Federation
Г. Рузбанова
Russian Federation
Г. Молчанова
Russian Federation
Т. Талалаева
Russian Federation
С. Хорева
Russian Federation
А. Ахадова
Russian Federation
References
1. Brunner H, Cockcroft JR, Deanfield J et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23 (2): 233-46.
2. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hipertens 2002; 20 (3): 353-5.
3. de Jong PE, de Zeeuw D. Renoprotective therapy: is it blood pressure or albuminuria that matters? Lancet 2005; 365: 913-4.
4. Bоhm M, Reil JC, Danchin N et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26 (1): 18-25.
5. Chobanian AV, Bakris GL, Black Hr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evalution, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72.
6. Knaght EL, Kramer HM, CurhanGC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003; 41 (3): 588-95.
7. Cottone S, Mule G, Nardi E et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 2007; 21 (2): 167-72.
8. Cirilo M, Senigalliesi L, Laurenzi M et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Arch Intern Med 1998; 158 (17): 1933-9.
9. Nahas AM, Bello AK. Chonic kidney disease: the global challenge. Lancet 2005; 365: 301-40.
10. Ruilope L, Segura J. Renal protection in diabetic patient benefits of first-line combination of perindopril-indapamide (Preterax). J Hypertens 2006; 24 (Suppl. 3): s9-s12.
11. Bibbons-Domingo K, Chertow GM, Fried LF et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166 (13): 1396-402.
12. Phillips RA, Diamond JA. Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension. In Oparil S, Weber MA (eds): Hypertension: a companion to Brenner & Rector's The Kidney, Edition Philadelphia, Pennsylvania, US: WB Saunders Company 2000; 244-77.
13. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology; 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 1105-87.
14. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. и др. Роль и целевой уровень отдельных компонентов ренин-ангиотензин-альдостероновой системы в развитии сердечно-сосудистых осложнений у больных артериальной гипертензией. Рос. кардиол. журн., 2009; 3 (77): 26-31.
15. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in men. Anatomic validation of the method. Circulation 1977; 55 (4): 613-8.
Review
For citations:
, , , , , . Systemic Hypertension. 2011;8(3):61-68.